Epitope specificity of anti-factor VIII antibodies from inhibitor positive acquired and congenital haemophilia A patients using synthetic peptides spanning A and C domains

 

 Buy Article Permissions and Reprints

Summary

Development of antibodies (Ab) that either block the function of coagulation factor VIII (FVIII) (inhibitors) or clear it from circulation, seriously complicate the treatment of haemophilia A patients with FVIII products. Autoantibodies which develop in subjects without congenital FVIII defects, cause acquired haemophilia, a rare but life-threatening coagulopathy. Identification of the FVIII epitopes to which inhibitor Abs bind will help understanding the mechanisms of inhibitor activity, and perhaps development of new therapies. Here, we examined the FVIII peptide sequence regions recognised by anti-FVIII Ab in the plasma of six congenital and one acquired haemophilia patients with high inhibitor titers (24.4–2000 BU/ml). We used indirect ELISA and overlapping synthetic peptides, 20 residues long, spanning the sequence of the A and C FVIII domains. None of the plasma samples reacted with A1, A3 or C1 domain peptides. Six plasmas reacted with A2 and/or C2 peptides. Peptides spanning residues A2–521–690 and C2–2251–2332 were recognised most frequently and strongly. They include residues that contribute to the binding sites for activated factor IX and phosphatidyl serine/ von Willebrand factor. These results suggest that anti-FVIII Abs share a pattern of antigen specificity in our panel of patients, and that exposed regions of the FVIII molecule that form functionally important binding sites elicit an intense Ab response.

• References

• 1 Lenting PJ, Van Mourik JA, Mertens K. The life cycle of coagulation factor VIII in view of its structure and function. Blood 1998; 92: 3983-3996.
  PubMedGoogle Scholar
• 2 Hoyer LW. Factor VIII inhibitors. Curr Opin Hematol 1995; 02: 365-371.
  CrossrefPubMedGoogle Scholar
• 3 Pipe SW. Recombinant clotting factors. Thromb Haemost 2008; 99: 840-850.
  Article in Thieme ConnectPubMedGoogle Scholar
• 4 Reding MT, Wu H, Krampf M. et al. Sensitization of CD4⁺T Cells to coagulation factor VIII: Response in congenital and acquired haemophilia patients and in healthy subjects. Thromb Haemost 2000; 84: 643-652.
  Article in Thieme ConnectPubMedGoogle Scholar
• 5 Cohen AJ, Kessler CM. Acquired inhibitors. Bail-lieres Clin Haematol 1996; 09: 331-354.
  CrossrefPubMedGoogle Scholar
• 6 Fulcher CA, Mahoney S, Zimmerman TS. Factor VIII inhibitor IgG subclass and factor VIII polypeptide specificity determined by immunoblotting. Blood 1987; 69: 1475-1480.
  PubMedGoogle Scholar
• 7 Scandella D, Mattingly M, Prescott R. A recombinant factor VIII A2 domain polypeptide quantitatively neutralizes human inhibitor antibodies that bind to A2. Blood 1993; 82: 1767-1775.
  PubMedGoogle Scholar
• 8 Palmer DS, Dudani AK, Drouin J. et al. Identification of novel factor VIII inhibitor epitopes using synthetic peptide arrays. Vox Sang 1997; 72: 148-161.
  CrossrefPubMedGoogle Scholar
• 9 Scandella D, Mattingly M, De Graaf S. et al. Localization of epitopes for human factor VIII inhibitor antibodies by immunoblotting and antibody neutralization. Blood 1989; 74: 1618-1626.
  PubMedGoogle Scholar
• 10 Lavigne-Lissalde G, Tarrade C, Lapalud P. et al. Simultaneous detection and epitope mapping of anti-factor VIII antibodies. Thromb Haemost 2008; 99: 1090-1096.
  Article in Thieme ConnectPubMedGoogle Scholar
• 11 Healy JF, Lubin IM, Nakai H. et al. Residues 484–508 contain a major determinant of the inhibitors epitope in the A2 domain of human factor VIII. J Biol Chem 1995; 270: 14505-14509.
  CrossrefPubMedGoogle Scholar
• 12 Scandella D, Gilbert GE, Shima M. et al. Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248–2312 which overlap a phospholipid binding Site. Blood 1995; 86: 1811-1819.
  PubMedGoogle Scholar
• 13 Lollar P. Characterization of factor VIII B-cell inhibitory epitopes. Thromb Haemost 1999; 82: 505-508.
  Article in Thieme ConnectPubMedGoogle Scholar
• 14 Healey JF, Barrow RT, Tamim HM. et al. Residues Glu2181-Val2243 contain a major determinant of the inhibitory epitope in the C2 domain of human factor VIII. Blood 1998; 92: 3701-3709.
  PubMedGoogle Scholar
• 15 Kasper C. A more uniform measurement of FVIII inhibitors. Thromb Diath Haemorrh 1975; 34: 869-872.
  PubMedGoogle Scholar
• 16 Gharagozlou S, Ghods R, Samadi Bahrami Z. et al. Characterization of human hybridoma clones isolated from haemophilia patients with specificity for different domains of coagulating factor VIII. Hum Antibodies 2003; 12: 67-76.
  PubMedGoogle Scholar
• 17 Hu GL, Okita DK, Conti-Fine BM. T cell recognition of the A2 domain of coagulation factor VIII in haemophilia patients and healthy subjects. J Thromb Haemost 2004; 02: 1908-1917.
  CrossrefPubMedGoogle Scholar
• 18 Pratt KP, Qian J, Ellaban E. et al. Immunodominant T-cell epitopes in the factor VIII C2 domain are located within an inhibitory antibody binding site. Thromb Haemost 2004; 92: 522-528.
  Article in Thieme ConnectPubMedGoogle Scholar
• 19 Reding MT, Okita DK, Diethelm-Okita BM. et al. Epitope repertoire of human CD4⁺ T cells on the A3 domain of coagulation factor VIII. J Thromb Haemost 2004; 02: 1385-1394.
  CrossrefPubMedGoogle Scholar
• 20 Reding MT, Okita DK, Diethelm-Okita BM. et al. Human CD4⁺ T-cell epitope repertoire on the C2 domain of coagulation factor VIII. J Thromb Haemost 2003; 01: 1777-1784.
  CrossrefPubMedGoogle Scholar
• 21 Hu GL, Okita DK, Diethelm-Okita BM. et al. Recognition of coagulation factor VIII by CD4⁺ T cells of healthy humans. J Thromb Haemost 2003; 01: 2159-2166.
  CrossrefPubMedGoogle Scholar
• 22 Sugihara T, Takahashi I, Kojima T. et al. Identification of Plasma antibody epitopes and gene abnormalities in Japanese haemophilia A patients with factor VIII inhibitor. Nagoya J Med Sci 2000; 63: 25-39.
  PubMedGoogle Scholar
• 23 Giambattista MD, Branckaert T, Laub R. Mapping of natural anti-factor VIII antibodies in plasma pools from healty donors: Use of rationally designed synthetic peptides. Biologicals 2001; 20: 229-232.
  PubMedGoogle Scholar
• 24 Albert T, Egler C, Jakuschev S. et al. The B-cell epitope of the monoclonal anti-facto VIII antibody ESH8 characterized by peptide array analysis. Thromb Haemost 2008; 99: 634-637.
  Article in Thieme ConnectPubMedGoogle Scholar
• 25 Scandella D. Epitope specificity and inactivation mechanisms of factor VIII inhibitor antibodies. Vox Sang 1999; 77 (Suppl. 01) 17-20.
  CrossrefPubMedGoogle Scholar
• 26 Scandella D. Human anti-factor VIII antibodies: Epitope localization and inhibitory function. Vox Sang 1996; 70 (Suppl. 01) 9-14.
  CrossrefPubMedGoogle Scholar
• 27 Scandella DH, Nakai H, Felch M. et al. In haemophilia A and autoantibody inhibitor patients: the factor VIII A2 domain and light chain are most immunogenic. Thromb Res 2001; 101: 377-385.
  CrossrefPubMedGoogle Scholar
• 28 Chaves DG, Velloso-Rodrigues C, Moreau V. et al. Reactivity profile of anti-factor VIII antibodies with designed synthetic peptides mimicking epitopes of the C2 and a1 domains. Br J Haematol 2008; 141: 708-715.
  CrossrefPubMedGoogle Scholar
• 29 Towfighi F, Gharagozlou S, Sharifian RA. et al. Comparative measurement of anti-factor VIII antibody by Bethesda assay and ELISA reveals restricted isotype profile and epitope specificity. Acta Haematol 2005; 114: 84-90.
  CrossrefPubMedGoogle Scholar
• 30 van Helden PM, van den Berg HM, Gouw SC. et al. IgG subclasses of anti-FVIII antibodies during immune tolerance induction in patients with haemophilia A. Br J Haematol 2008; 142: 644-652.
  CrossrefPubMedGoogle Scholar
• 31 Spiegel Jr PC, Stoddard BL. Optimization of factor VIII replacement therapy: Can structural studies help in evading antibody inhibitors?. Br J Haematol 2002; 119: 310-322.
  CrossrefPubMedGoogle Scholar
• 32 Van den Brink EN, Turendhout EAM, Bank CMC. et al. Molecular analysis of human anti-factor VIII antibodies by V gene phage display identifies a new epitope in the acidic region following the A2 domain. Blood 2000; 95: 540-545.
  PubMedGoogle Scholar
• 33 Saenko El, Scandella D. The acidic region of the factor VIII light chain and the C2 domain together form the high affinity binding site for von Willebrand factor. J Biol Chem 1997; 272: 18007-18014.
  CrossrefPubMedGoogle Scholar
• 34 Gilbert GE, Drinkwater D. Specific membrane binding of factor VIII is mediated by O- PhosphoL-Serine, a moiety of phosphatidylserine. Biochemistry 1993; 32: 9577-9585.
  CrossrefPubMedGoogle Scholar
• 35 Jacquemin MG, Desqueper BG, Benhida A. et al. Mechanism and kinetics of factor VIII inactivation: Study with an IgG4 monoclonal antibody derived from a haemophilia A Patient with inhibitor. Blood 1998; 92: 496-506.
  PubMedGoogle Scholar
• 36 Meeks SL, Healey JF, Parker ET. et al. Non-classical anti-C2 domain antibodies are present in patients with factor VIII inhibitors. Blood 2008; 112: 1151-1153.
  CrossrefPubMedGoogle Scholar
• 37 Fulcher CA, Lechner K, Mahoney SDG. Immunoblot analysis shows changes in factor VIII inhibitor chain specificity in factor VIII inhibitor over time. Blood 1988; 72: 1348-1356.
  PubMedGoogle Scholar
• 38 Hoyer LW, Scandella D. Factor VIII inhibitors: Structure and function in autoantibody and haemophilia A Patients. Semin Hematol 1994; 31 (Suppl. 04) 1-5.
  PubMedGoogle Scholar
• 39 Gharagozlou S, Kardar GA, Rabbani H. et al. Molecular analysis of the heavy chain variable region genes of human hybridoma clones specific for coagulation factor VIII. Thromb Haemost 2005; 94: 1131-1137.
  Article in Thieme ConnectPubMedGoogle Scholar
• 40 Bellone M, Karachunski P, Ostlie N. et al. Clustering of B and T epitopes within short sequence regions of the nicotinic acetylcholine receptor. Scand J Immunol 1995; 41: 135-140.
  CrossrefPubMedGoogle Scholar